275 related articles for article (PubMed ID: 23457458)
1. Dopamine-mediated oxidation of methionine 127 in α-synuclein causes cytotoxicity and oligomerization of α-synuclein.
Nakaso K; Tajima N; Ito S; Teraoka M; Yamashita A; Horikoshi Y; Kikuchi D; Mochida S; Nakashima K; Matsura T
PLoS One; 2013; 8(2):e55068. PubMed ID: 23457458
[TBL] [Abstract][Full Text] [Related]
2. Alpha-Synuclein Fibrils Interact with Dopamine Reducing its Cytotoxicity on PC12 Cells.
Khalife M; Morshedi D; Aliakbari F; Tayaranian Marvian A; Mohammad Beigi H; Azimzadeh Jamalkandi S; Pan-Montojo F
Protein J; 2015 Aug; 34(4):291-303. PubMed ID: 26250981
[TBL] [Abstract][Full Text] [Related]
3. Redox reactions of the α-synuclein-Cu(2+) complex and their effects on neuronal cell viability.
Wang C; Liu L; Zhang L; Peng Y; Zhou F
Biochemistry; 2010 Sep; 49(37):8134-42. PubMed ID: 20701279
[TBL] [Abstract][Full Text] [Related]
4. Formation of large oligomers of DOPAL-modified α-synuclein is modulated by the oxidation of methionine residues located at C-terminal domain.
Coelho-Cerqueira E; de Araújo Correia Campos C; Follmer C
Biochem Biophys Res Commun; 2019 Feb; 509(2):367-372. PubMed ID: 30591215
[TBL] [Abstract][Full Text] [Related]
5. Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions.
Zhou W; Long C; Reaney SH; Di Monte DA; Fink AL; Uversky VN
Biochim Biophys Acta; 2010 Mar; 1802(3):322-30. PubMed ID: 20026206
[TBL] [Abstract][Full Text] [Related]
6. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.
Gorbatyuk OS; Li S; Sullivan LF; Chen W; Kondrikova G; Manfredsson FP; Mandel RJ; Muzyczka N
Proc Natl Acad Sci U S A; 2008 Jan; 105(2):763-8. PubMed ID: 18178617
[TBL] [Abstract][Full Text] [Related]
7. Identification of an Alternatively Spliced α-Synuclein Isoform That Generates a 41-Amino Acid N-Terminal Truncated Peptide, 41-syn: Role in Dopamine Homeostasis.
Vinnakota RL; Yedlapudi D; Manda KM; Bhamidipati K; Bommakanti KT; RangaLakshmi GS; Kalivendi SV
ACS Chem Neurosci; 2018 Dec; 9(12):2948-2958. PubMed ID: 29996045
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of α-Synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of α-Synuclein in the pathogenesis of Parkinson's Disease and related disorders.
Lu Y; Prudent M; Fauvet B; Lashuel HA; Girault HH
ACS Chem Neurosci; 2011 Nov; 2(11):667-75. PubMed ID: 22860160
[TBL] [Abstract][Full Text] [Related]
9. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations.
Norris EH; Giasson BI; Hodara R; Xu S; Trojanowski JQ; Ischiropoulos H; Lee VM
J Biol Chem; 2005 Jun; 280(22):21212-9. PubMed ID: 15817478
[TBL] [Abstract][Full Text] [Related]
10. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
Sharma N; Rao SP; Kalivendi SV
Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
[TBL] [Abstract][Full Text] [Related]
11. Methionine oxidation in α-synuclein inhibits its propensity for ordered secondary structure.
Ponzini E; De Palma A; Cerboni L; Natalello A; Rossi R; Moons R; Konijnenberg A; Narkiewicz J; Legname G; Sobott F; Mauri P; Santambrogio C; Grandori R
J Biol Chem; 2019 Apr; 294(14):5657-5665. PubMed ID: 30755483
[TBL] [Abstract][Full Text] [Related]
12. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
[TBL] [Abstract][Full Text] [Related]
13. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
Xu S; Chan P
Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
[TBL] [Abstract][Full Text] [Related]
14. Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation.
Leong SL; Pham CL; Galatis D; Fodero-Tavoletti MT; Perez K; Hill AF; Masters CL; Ali FE; Barnham KJ; Cappai R
Free Radic Biol Med; 2009 May; 46(10):1328-37. PubMed ID: 19248830
[TBL] [Abstract][Full Text] [Related]
15. Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence.
Mazzulli JR; Armakola M; Dumoulin M; Parastatidis I; Ischiropoulos H
J Biol Chem; 2007 Oct; 282(43):31621-30. PubMed ID: 17785456
[TBL] [Abstract][Full Text] [Related]
16. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease.
McFarland NR; Fan Z; Xu K; Schwarzschild MA; Feany MB; Hyman BT; McLean PJ
J Neuropathol Exp Neurol; 2009 May; 68(5):515-24. PubMed ID: 19525899
[TBL] [Abstract][Full Text] [Related]
17. Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models.
Zhu Q; Zhuang XX; Chen JY; Yuan NN; Chen Y; Cai CZ; Tan JQ; Su HX; Lu JH
Phytomedicine; 2021 Jul; 87():153578. PubMed ID: 34038839
[TBL] [Abstract][Full Text] [Related]
18. Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.
Lewis KA; Yaeger A; DeMartino GN; Thomas PJ
J Bioenerg Biomembr; 2010 Feb; 42(1):85-95. PubMed ID: 20148295
[TBL] [Abstract][Full Text] [Related]
19. Cytoprotective effect of chlorogenic acid against α-synuclein-related toxicity in catecholaminergic PC12 cells.
Teraoka M; Nakaso K; Kusumoto C; Katano S; Tajima N; Yamashita A; Zushi T; Ito S; Matsura T
J Clin Biochem Nutr; 2012 Sep; 51(2):122-7. PubMed ID: 22962530
[TBL] [Abstract][Full Text] [Related]
20. Modulation of alpha-synuclein aggregation by dopamine: a review.
Leong SL; Cappai R; Barnham KJ; Pham CL
Neurochem Res; 2009 Oct; 34(10):1838-46. PubMed ID: 19444607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
